LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis

Onco Targets Ther. 2020 Mar 26:13:2527-2535. doi: 10.2147/OTT.S241578. eCollection 2020.

Abstract

Background: Increasing researches have revealed a critical role of long noncoding RNAs (lncRNAs) in tumor progression. LINC00665 is a poorly investigated lncRNA. In this research, we sought to determine the potential role of LINC00665 in prostate cancer (PC) progression.

Methods: LINC00665 expression was analyzed by bioinformatics method and qRT-PCR. Proliferation was determined via CCK8 and colony formation assays. Transwell assay was conducted to analyze migration and invasion. Xenograft assay was used to test the roles of LINC00665 in vivo. Luciferase reporter assay, pulldown assay and RIP assay were utilized to confirm the interaction between LINC00665 and miR-1224-5p.

Results: LINC00665 expression was increased in PC samples in contrast to control tissues, according to bioinformatics analysis and qRT-PCR validation. LINC00665 high expression was related to a poor prognosis. LINC00665 knockdown markedly attenuated growth and metastasis of PC cells and impaired tumor propagation in vivo. Mechanistic investigation revealed that LINC00665 was the sponge for miR-1224-5p. By inhibiting miR-1224-5p level, LINC00665 dramatically promoted the expression of SND1 in PC cells. Ectopic expression of SND1 significantly rescued the effects of LINC00665 silencing.

Conclusion: LINC00665 is a novel oncogenic gene in PC by targeting miR-1224-5p/SND1 pathway and may be a therapeutic target.

Keywords: LINC00665; SND1; miR-1224-5p; progression; prostate cancer.

Grants and funding

Our work was granted by Wenzhou Science and Technology Project (Y20170231) and Zhejiang Provincial Natural Science Foundation of China under Grant (LQ20H050001 and LY20H160013).